Status:
COMPLETED
Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost
Lead Sponsor:
Innovative Medical
Conditions:
Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Evaluate the relative efficacy and tolerability of Alphagan P compared to Trusopt as adjunctive therapy
Eligibility Criteria
Inclusion
- · Male or female \> 18 years of age
- Diagnosis of open-angle glaucoma or ocular hypertension
- IOP \> 16 mm Hg in each eye at the latanoprost -treated baseline evaluation
- Presently on latanoprost monotherapy for at least 6 weeks
- Ability to provide informed consent and likely to complete all study visits
Exclusion
- · Known contraindication or allergy to brimonidine or any of its components
- Subjects must be naive to brimonidine 0.2% or brimonidine Purite 0.15% and dorzolamide 2%
- Uncontrolled systemic disease
- Active ocular disease other than glaucoma or ocular hypertension (e.g. uveitis, ocular infections, or severe dry eye). Patients with chronic mild blepharitis, cataract, age-related macular degeneration, or background diabetic retinopathy may be enrolled at the discretion of the investigator.
- Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear product is allowed).
- Corneal abnormalities
- History of intraocular surgery within the last 3 months
- Female patients of childbearing potential who are pregnant, lactating, planning a pregnancy, or not using a reliable form of birth control
- Visual field loss, which in the opinion of the investigator, is functionally significant, or evidence of progressive visual field loss within the last year.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00348400
Last Update
June 1 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Noecker
Pittsburgh, Pennsylvania, United States, 15213